BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 11841400)

  • 1. The TEL-AML1 real-time quantitative polymerase chain reaction (PCR) might replace the antigen receptor-based genomic PCR in clinical minimal residual disease studies in children with acute lymphoblastic leukaemia.
    de Haas V; Breunis WB; Dee R; Verhagen OJ; Kroes W; van Wering ER; van Dongen JJ; van den Berg H; van der Schoot CE
    Br J Haematol; 2002 Jan; 116(1):87-93. PubMed ID: 11841400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
    Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
    Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia.
    Cayuela JM; Baruchel A; Orange C; Madani A; Auclerc MF; Daniel MT; Schaison G; Sigaux F
    Blood; 1996 Jul; 88(1):302-8. PubMed ID: 8704188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantification of TEL-AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia.
    Drunat S; Olivi M; Brunie G; Grandchamp B; Vilmer E; Bièche I; Cavé H
    Br J Haematol; 2001 Aug; 114(2):281-9. PubMed ID: 11529845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia.
    Nakao M; Yokota S; Horiike S; Taniwaki M; Kashima K; Sonoda Y; Koizumi S; Takaue Y; Matsushita T; Fujimoto T; Misawa S
    Leukemia; 1996 Sep; 10(9):1463-70. PubMed ID: 8751464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-time quantification of TEL-AML1 fusion transcripts for MRD detection in relapsed childhood acute lymphoblastic leukaemia. Comparison with antigen receptor-based MRD quantification methods.
    Taube T; Eckert C; Körner G; Henze G; Seeger K
    Leuk Res; 2004 Jul; 28(7):699-706. PubMed ID: 15158091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease studies are beneficial in the follow-up of TEL/AML1 patients with B-precursor acute lymphoblastic leukaemia.
    de Haas V; Oosten L; Dee R; Verhagen OJ; Kroes W; van den Berg H; van der Schoot CE
    Br J Haematol; 2000 Dec; 111(4):1080-6. PubMed ID: 11167743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid quantitative detection of TEL-AML1 fusion transcripts in pediatric acute lymphoblastic leukemia by real-time reverse transcription polymerase chain reaction using fluorescently labeled probes.
    Bolufer P; Barragán E; Verdeguer A; Cervera J; Fernández JM; Moreno I; Lerma E; Esquembre C; Tasso M; Fuster V; Bermúdez M; Sanz MA
    Haematologica; 2002 Jan; 87(1):23-32. PubMed ID: 11801462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia.
    Boeckx N; Willemse MJ; Szczepanski T; van der Velden VH; Langerak AW; Vandekerckhove P; van Dongen JJ
    Leukemia; 2002 Mar; 16(3):368-75. PubMed ID: 11896540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence of TEL-AML1 transcript in acute lymphoblastic leukemia in long-term remission.
    Endo C; Oda M; Nishiuchi R; Seino Y
    Pediatr Int; 2003 Jun; 45(3):275-80. PubMed ID: 12828580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease with TEL-AML1 fusion transcript in childhood acute lymphoblastic leukaemia with t(12;21).
    Satake N; Kobayashi H; Tsunematsu Y; Kawasaki H; Horikoshi Y; Koizumi S; Kaneko Y
    Br J Haematol; 1997 Jun; 97(3):607-11. PubMed ID: 9207408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes.
    Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ
    Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript.
    Pallisgaard N; Clausen N; Schroder H; Hokland P
    Genes Chromosomes Cancer; 1999 Dec; 26(4):355-65. PubMed ID: 10534771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping.
    Malec M; van der Velden VH; Björklund E; Wijkhuijs JM; Söderhäll S; Mazur J; Björkholm M; Porwit-MacDonald A
    Leukemia; 2004 Oct; 18(10):1630-6. PubMed ID: 15295608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Persistence of TEL-AML1 fusion gene as minimal residual disease has no additive prognostic value in CD 10 positive B-acute lymphoblastic leukemia: a FISH study.
    Mosad E; Hamed HB; Bakry RM; Ezz-Eldin AM; Khalifa NM
    J Hematol Oncol; 2008 Oct; 1():17. PubMed ID: 18928518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
    van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
    Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring.
    Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G
    Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse.
    van der Velden VH; Brüggemann M; Hoogeveen PG; de Bie M; Hart PG; Raff T; Pfeifer H; Lüschen S; Szczepański T; van Wering ER; Kneba M; van Dongen JJ
    Leukemia; 2004 Dec; 18(12):1971-80. PubMed ID: 15470492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement.
    Viehmann S; Teigler-Schlegel A; Bruch J; Langebrake C; Reinhardt D; Harbott J
    Leukemia; 2003 Jun; 17(6):1130-6. PubMed ID: 12764380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.
    Uphoff CC; MacLeod RA; Denkmann SA; Golub TR; Borkhardt A; Janssen JW; Drexler HG
    Leukemia; 1997 Mar; 11(3):441-7. PubMed ID: 9067587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.